Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32–35 weeks’ gestational age with more informed use of risk factors?

References

• Simoes EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002;3(Suppl 1):S26–33
   Google Scholar
• Law BJ, MacDonald N, Langley J, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? Paediatr Child Health 1998;3:402–4
   PubMedGoogle Scholar
• Liese JG, Grill E, Fischer B, et al; Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230–6
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806–14
   PubMed Web of Science ®Google Scholar
• The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–7
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 2004;23:815–20
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788–93
   PubMed Web of Science ®Google Scholar
• Simões EA, Carbonell-Estrany X, Fullarton JR, et al; European RSV Risk Factor Study Group; European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study. Respir Res 2008;9:78
   PubMed Web of Science ®Google Scholar
• Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk factor scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471–80
   PubMed Web of Science ®Google Scholar
• Medici MC, Arcangeletti MC, Rossi GA, et al; Osservatorio VRS Study Group. Four-year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the “Osservatorio VRS” Study (2000–2004). New Microbiologica 2006;29:35–43
   PubMed Web of Science ®Google Scholar
• Simões EA, Carbonell-Estrany X, Fullarton JR, et al; European RSV Risk Factor Study Group. European risk factors’ model to predict hospitalization of premature infants born 33–35 weeks’ gestational age with respiratory syncytial virus: validation with Italian data. J Matern Fetal Neonatal Med 2011;24:152–7
   PubMed Web of Science ®Google Scholar
• Grimaldi M, Cornet B, Milou C, Gouyon JB. [Prospective regional study of an epidemic of respiratory syncytial virus (RSV) bronchiolitis] [Article in French]. Arch Pediatr 2002;9:572–80
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Simões EA, Fullarton JR, et al; European RSV Risk Factor Study Group. Validation of a model to predict hospitalization due to RSV of infants born at 33–35 weeks’ gestation. J Perinat Med 2010;38:411–17
   PubMed Web of Science ®Google Scholar
• Figueras Aloy J, Carbonell Estrany X; Comité de Estándares de la Sociedad Española de Neonatología. [Recommendations for the use of palivizumab in the prevention of respiratory syncytial virus infection in late preterm infants (32(1) to 35(0) weeks of gestation)]. An Pediatr (Barc) 2010;73:98.e1–4
   Google Scholar
• Rondini G, Macagno F, Barberi I. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonatologica 2004;1:1–11
   Google Scholar
• German Society for Paediatric Infectious Diseases Association (DGPI). Stellungnahme zur Prophylaxe von schweren RSV-Erkrankungen bei Risikokindern mit Palivizumab. Available from: www.dgpi.de [last accessed August 2011]
   Google Scholar
• Samson L; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14:521–32
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL
   Google Scholar
• Smart KA, Lanctôt KL, Paes BA. Rebuttal: palivizumab for the prevention of respiratory syncytial infection. Can Fam Physician 2010;56:988–91
   PubMed Web of Science ®Google Scholar
• Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010;29:374–6
   PubMed Web of Science ®Google Scholar
• Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugen 1936;7:179–88
   Google Scholar
• SPSS Inc. 444 N. Michigan Avenue, Chicago, IL. Available from: http://www.spss.com.hk/
   Google Scholar
• Doering G, Gusenleitner W, Belohradsky BH, et al. The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks’ gestational age. Pediatr Infect Dis J 2006;25:1188–90
   PubMed Web of Science ®Google Scholar
• Lanari M, Adorni F, Silvestri M, et al; Italian Study Group on Risk Factors for RSV-related Hospitalization. The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33 weeks GA or more: preliminary results. Early Hum Dev 2011;87:S43–6
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Fullarton JR, Gooch KL, Figueras-Aloy J. The evolution of risk factors for respiratory syncytial virus (RSV)-related hospitalisation in infants born at 32–35 weeks’ gestational age: time-based analysis using data from the FLIP-2 study. J Perinat Med 2012;40:685–91
   PubMed Web of Science ®Google Scholar
• Bisson GP, Gross R, Strom JB, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006;20:1613–19
   PubMed Web of Science ®Google Scholar
• Timsit JF, Fosse JP, Troche G, et al; the OUTCOMEREA Study Group France. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med 2002;30:2003–13
   PubMed Web of Science ®Google Scholar
• Riker MW, Kennedy C, Winfrey BS, et al. Validation and refinement of the difficult intravenous access score: a clinical prediction rule for identifying children with difficult intravenous access. Acad Emerg Med 2011;18:1129–34
   PubMed Web of Science ®Google Scholar
• Brubaker PH. Do not be statistically cenophobic. Time to ROC and roll. JCRP 2008;28:420–1
   Google Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452–4
   PubMed Web of Science ®Google Scholar
• Robbins JM, Tilford JM, Jacobs RF, et al. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med 1998;152:358–66
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712–20
   PubMed Web of Science ®Google Scholar
• Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;165:498–505
   PubMed Web of Science ®Google Scholar
• Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865–70
   PubMed Web of Science ®Google Scholar
• Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004;23:S193–201
   PubMedGoogle Scholar
• Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991;133:1135–51
   PubMed Web of Science ®Google Scholar
• Joffe S, Escobar GJ, Black SB, et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894–9
   PubMed Web of Science ®Google Scholar
• Eriksson M, Bennet R, Rotzen-Ostlund M, et al. Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting. Acta Paediatr 2002;91:593–8
   PubMed Web of Science ®Google Scholar
• Heikkinen T, Valkonen H, Lehtonen L, et al. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed 2005;90:F64–8
   PubMedGoogle Scholar
• Law BJ, MacDonald N, Langley JM, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent? Paediatr Child Health 1998;3:402–4
   PubMedGoogle Scholar
• Naver L, Eriksson M, Ewald U, et al. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Paediatr 2004;93:1470–3
   PubMed Web of Science ®Google Scholar
• Bentley A, Filipovic I, Gooch K, Buesch K. A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the UK. Thorax 2011;66:A136–7
   Google Scholar